Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Aggressive retinal astrocytoma associated with tuberous sclerosis.

Tomida M, Mitamura Y, Katome T, Eguchi H, Naito T, Harada T.

Clin Ophthalmol. 2012;6:715-20. doi: 10.2147/OPTH.S31759. Epub 2012 May 9.

2.

Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.

Saito W, Kase S, Ohgami K, Mori S, Ohno S.

Acta Ophthalmol. 2010 May;88(3):377-80. doi: 10.1111/j.1755-3768.2008.01331.x. Epub 2010 Sep 5.

3.

Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Smith JM, Steel DH.

Cochrane Database Syst Rev. 2015 Aug 7;(8):CD008214. doi: 10.1002/14651858.CD008214.pub3. Review.

PMID:
26250103
4.

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.

Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C.

Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48.

PMID:
18779710
5.

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.

Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A.

Retina. 2006 Nov-Dec;26(9):999-1005.

PMID:
17151486
6.

Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection.

Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP, Ishibashi T.

Am J Ophthalmol. 2010 Aug;150(2):223-229.e1. doi: 10.1016/j.ajo.2010.03.016. Epub 2010 Jun 9.

PMID:
20542485
7.

Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.

Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.

Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.

PMID:
26038338
8.

Vitreous web after pars plana vitrectomy and bevacizumab with fluid-air exchange.

Chiang A, Reddy S, Tsui I, Hubschman JP.

Semin Ophthalmol. 2011 Jan;26(1):25-7. doi: 10.3109/08820538.2010.541316.

PMID:
21275601
9.

Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema.

Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, Yamashita H, Takeuchi S.

Am J Ophthalmol. 2003 Jan;135(1):14-9.

PMID:
12504691
10.

Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.

Kychenthal A, Dorta P.

Retina. 2010 Apr;30(4 Suppl):S32-6. doi: 10.1097/IAE.0b013e3181ca146b.

PMID:
20224474
11.

Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.

Jun JH, Kim YC, Kim KS.

Korean J Ophthalmol. 2008 Sep;22(3):190-3. doi: 10.3341/kjo.2008.22.3.190.

13.

Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.

Melamud A, Stinnett S, Fekrat S.

Am J Ophthalmol. 2008 Jul;146(1):91-5. doi: 10.1016/j.ajo.2008.03.014. Epub 2008 May 2.

PMID:
18455144
14.

Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.

Saito W, Kase S, Fujiya A, Dong Z, Noda K, Ishida S.

Retina. 2013 Oct;33(9):1959-67. doi: 10.1097/IAE.0b013e3182923490.

PMID:
23652580
15.

Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X; T├╝bingen Bevacizumab Study Group, Grisanti S.

Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1. doi: 10.1016/j.ophtha.2008.04.023. Epub 2008 Aug 16.

PMID:
18708261
16.
17.

[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].

Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.

J Fr Ophtalmol. 2011 Jun;34(6):376-81. doi: 10.1016/j.jfo.2011.03.004. Epub 2011 May 7. French.

18.

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.

Ophthalmology. 2006 Mar;113(3):363-372.e5. Epub 2006 Feb 3.

PMID:
16458968
19.
20.

Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study.

Patwardhan SD, Azad R, Shah BM, Sharma Y.

Retina. 2011 May;31(5):866-70. doi: 10.1097/IAE.0b013e3181f2a27f.

PMID:
21301382

Supplemental Content

Support Center